meglumine antimoniate
Small moleculeexperimental
Meglumine antimoniate is a medicine used to treat leishmaniasis. This includes visceral, mucocutaneous, and cutaneous leishmaniasis. It is given by injection into a muscle or into the area infected. — Wikipedia
Clinical trial activity
6 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started May 31, 2007 (NCT04340128)
Timeline
Indications
Mechanism of action
- LeishmaniaINHIBITOR
Leishmania inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeglumine antimoniate ↗
Also known as
- liposomal meglumine antimoniate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06822478 | Phase 3 | Oct 31, 2025 | INNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES (CIDEPRO), Universidad de Antioquia |
| NCT06011343 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2023 | Federal University of Bahia, Instituto Gonçalo Muniz FIOCRUZ BA |
| NCT04515186 | Phase 3 | Nov 9, 2020 | Cayetano Heredia University, Drugs for Neglected Diseases Initiative, Federal University of Bahia, Federal University of Mato Grosso do Sul, Fundacion Nacional de Dermatologia, Instituto Conmemorativo Gorgas de Estudios de la Salud |
| NCT03294161 | Phase 2 | Dec 31, 2014 | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Federal University of Bahia, Pontifical Catholic University of Rio Grande do Sul |
| NCT01050777 | Early Phase 1 (Phase 1) | Mar 1, 2011 | Isfahan University, Mashhad University of Medical Sciences, University of Tehran |
| NCT04340128 | Phase 3 | May 31, 2007 | Kerman University of Medical Sciences, Mashad University of Medical Sciences, Mashhad University of Medical Sciences, University of Tehran |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (16)
16 organizations
Page 1 / 1